Inactive Instrument

Exactus Inc Stock OTC Bulletin Board

Equities

US30066P1021

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Exactus Inc
Sales 2022 1.63M Sales 2023 2.38M Capitalization 2.65M
Net income 2022 -9M Net income 2023 -8M EV / Sales 2022 11.6 x
Net Debt 2022 17.85M Net Debt 2023 21.53M EV / Sales 2023 10.1 x
P/E ratio 2022
-0.11 x
P/E ratio 2023
-0.31 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 0%
More Fundamentals * Assessed data
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Panacea Life Sciences Holdings, Inc. completed the acquisition of N7 Enterprises, Inc. CI
Panacea Life Sciences Holdings, Inc. entered into an Asset Purchase Agreement to acquire PÜR LIFE Medical, Inc. CI
Panacea Life Sciences Holdings, Inc. completed the acquisition of Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp. for $7.8 million. CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Panacea Life Sciences Holdings, Inc. entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million. CI
Panacea Life Sciences Holdings, Inc. agreed to acquire Nitro Kava & Kratom. CI
Panacea Life Sciences Holdings, Inc. entered into agreements acquire 8 Retail Locations in the Tampa, Florida. CI
Panacea Life Sciences Holdings, Inc. Distribution Division Signs Exclusive Distribution Agreement with QR Joy to Distribute U.S. Top Fume Disposable Vape Devices in the U.K CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Panacea Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt CI
Panacea Life Sciences Holdings, Inc. entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million. CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 67 21-06-29
Comptroller/Controller/Auditor 36 17-12-31
- -
Members of the board TitleAgeSince
Chief Executive Officer 67 21-06-29
Chief Executive Officer 66 20-04-28
More insiders
Exactus, Inc. is a healthcare company. The Company is focused on manufacturing hemp derived Cannabidiol (CBD) products. It sells its CBD products through its Exactus brand and white label products to third-party resellers. It is also engaged in producing industrial hemp from farms in Oregon. Its products product line includes hemp flower, pre-rolled hemp flower, topicals, tinctures and concentrates. It also offers point-of-care diagnostic tools to analyze biometric markers in a drop of blood. Its FibriLyzer product provides solution to assess the fibrinolytic status of patients in a broad range of applications, including surgery, trauma, orthopedics, heart, stroke and chronic coronary disease management. Its MatriLyzer product detects the initial occurrence or the recurrence of cancer during routine office visits.
More about the company